Staying Long Against High-Frequency Traders
Summary
Putting the legal and trading case arguments against the remarks sent out by Citron Research Analyst, March 9, 2020, then threatened, used High-Frequency Trading with short-selling actions immediately the same day to drive down share value of Inovio Pharmaceutical INO.
How different was the announcement by GlaxoSmithKline, GSX, and Sanofi-Aventis S.A., SNY their combined announcement April 14, 2020, in joining developing a vaccine for COVID-19 from that of Inovio INO-4800?
Price-Targets PT Inovio INO
When Citron's law-firms posting of class-action law-suits with their Twitter Tweets broke or challenged SEC laws on SEC 72 hours by setting into motion, their uses of High-Frequency Short-Selling Campaign against Inovio shareholders value.
Bullish Reversals identified with INO.
(Click on image to enlarge)
Inovio Pharmaceuticals Inc., (c) 2020
Inovio Stock Roiled With High-Frequency Short-Selling as Citron Research, Law Firms
Push Back on Coronavirus Vaccine Announcement
DJ News Feeds, March 9, 2020
Citron Research later posted a tweet saying regulators should investigate the "ludicrous and dangerous claim that they designed a vaccine in 3 hours." The Citron Research tweet sent the stock much lower by High-Frequency Trading (HFT) short-selling, driving the INO share price down, giving rise to possible grounds for a lawsuit by investors who lost money, multiple law firms who climbed aboard as HFT and said,
$INO SEC should immediately HALT this stock and investigate the ludicrous and dangerous claim that they designed a vaccine in 3 hours. This has been a serial stock promotion for years. This will trade back to $2. Investors have been warned.
— Citron Research (@Citron Research) March 9, 2020
A Common Practice
Lawyers and firms have long made a practice of jumping on the news and putting efforts to drive down shareholder value by HFT short-selling from potentially questionable activity by publicly traded companies as we are commenting on the Inovio by announcing they're seeking shareholders to sue the company.
The degree of success for such lawsuits isn't immediately clear, but often they either aren't filed or don't result in a big win for shareholders.
What Inovio Said:
The law firms all said they were looking into an early March press release from Inovio in which its President and CEO Joseph Kim, said: "We designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19."
The company also said it can develop a vaccine by the end of the year.
Citron Research later posted a tweet saying, regulators should investigate the "ludicrous and dangerous claim that they designed a vaccine in 3 hours." The Citron Research tweet sent the stock lower, giving rise to possible grounds for a lawsuit by investors who lost money, multiple law firms said.
(INO). SEC should immediately HALT this stock and investigate the ludicrous and dangerous claim that they designed a vaccine in 3 hours. This has been a serial stock promotion for years. This will trade back to $2. Investors have been warned.
— Citron Research (@Citron Research) March 9, 2020
Among the lawyers and firms seeking investors for a possible suit were Glancy, Prongay & Murray; Howard G. Smith'; Bronstein, Gewirtz & Grossman; and the Pomerantz Law Firm.
THE FACTS
The SEC, FDA, and all other regulatory agencies have investigated Citron Research Analyst claims have fully reviewed the statements made by Inovio Pharmaceuticals, Dr. Joseph Kim, as Tweeted by Citron, and cited by law firms who filed Class-Action lawsuits causing downside pressures on shareholders' value.
The SEC and FDA found the statements made by Dr. Kim, CEO of Inovio Pharmaceuticals, to be true, as the FDA approved Inovio’s INO-4800 for Phase1/2 human testing. Furthermore, not only was INO-4800 approved for Phase 1, but it has two active COVID-19 Vaccine trials now in progress for results pending later this Summer in the United States, and in South Korea on the need to protect our U.S. Forces stationed in South Korea and eventually all the world.
Both these Phase 1 / 2 COVID-19 Vaccine-Trials funded by the Department of Defense DOD, CEPI, Bill and Melinda Gates Foundation, along with other funding by a further 150 million diluted share offering with Stifel Nicholas, as filed SEC 8-form. It must also be stated again, President Trump brought aboard, INOVIO, most renowned Epidemiologists to Trump's task force. These renowned Inovio Epidemiologists, brought in the early beginning stages, as stages for advising Vice-president Pence, and President Trump, himself, on what expectations as to death rates and virus spreads. Inovio was instrumental with their help with guidelines developed for the mitigation and containing this newest strain of China’s Novel Coronavirus COVID-19.
Here is the problem we see with Citron and the law suits filed by the news events applied towards INO, but vagrantly miss-using the significant SEC laws of no trading of any kind for 72 hour pre-post news worthy events, as rules for publicly making claims or news worthy events as claims that were not objective, but as subjective, tweeted by Citron--chose to announce and then trade HFT along with law-firms using short-selling pushing the $INO share price down, with also putting Short-selling orders as traded broke the SEC-law prohibits any potential insider knowledge--as was conducted again, by more than a few law firms also using HFT within the SEC 72 hour freeze for insider trading advantages, as what we saw occur, with the official / un-official Twitter-Tweet as their form in trying to direct large Short-Selling in High Frequency Traders HFT, as also the planned legal filing announcements tragically played by the law-firms moving the actual total shares of $INO availed for trading in borrowing of these $INO shares to well over 38% of the entire issued $INO shares sold short, as to jump on $INO and drive their share price down towards the threatened, two $2 dollar levels, as promised and threatened by Citron’s Tweet.
THE MESSAGE
Citron Research Analyst made a Short-Selling SEC 72 Hour news or subjective comment and brought huge block-trade short-selling traders, alert that the SEC should have halted all Short-Sellers, because of the Twitter Tweet can be considered a volatile statement, in that, the legal class action suits should have been filed against Citron Research for their false claims made against Inovio $INO, in a deliberate act of causing significant shareholder losses due to their Tweet sent, March 9, 2020.
Currently, we have price targets for $INO PT’s near-term and long-term. The near-term PT is $37-$48 dollars a share. The longer-term price-target is between $72 - $98 dollars a share in the 2020-2021 fiscal reporting quarters. We make these PT’s based on Inovio huge pipeline of candidates for FDA approvals over these next two years or less.
THE COMPARISON
How different was the announcement by Glaxo Smith Kline, $GSX and Sanofi-Aventis S.A., $SNY their combined announcement April 14, 2020
April 6, 2020 02:14 PM ET (BZ Newswire) -- News
Sanofi (NASDAQ: SNY) announces that it has successfully priced tap offerings of EUR 500 million of notes (the "Notes") on two outstanding tranches:
- €250 million fixed-rate notes, increasing the total principal amount of the tranche due April 2025 bearing interest at an annual rate of 1.000% to €1 billion
- €250 million fixed-rate notes, increasing the total principal amount of the tranche due April 2030 bearing interest at an annual rate of 1.500% to €1 billion
The Notes are being issued of the company's Euro Medium Term Note Programme.
The transactions enable the company to lower its average cost of debt and extend the average maturity of its debt.
Sanofi intends to use the net proceeds of the offerings for general corporate purposes.
The transactions enable the company to lower its average cost of debt and extend the average maturity of its debt.
Sanofi intends to use the net proceeds of the offerings for general corporate purposes.
Crédit Agricole CIB, HSBC, Bank of America Securities and Société Générale acted as Global Coordinators and Bookrunners for the offering
Copyright © 2020 Benzinga (BZ Newswire, Financial Market Data & API's - Benzinga). Benzinga does not provide investment advice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (Benzinga Pro | Fast Stock Market News).
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
- Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
- Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021
PARIS and LONDON – April 14, 2020 - Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculoviral expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.
GSK will contribute its proven pandemic adjuvant technology. The use of an adjuvant can be of importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.
As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone.” says Paul Hudson, Chief Executive Officer, Sanofi. “That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus.”
“This collaboration brings together two of the world’s largest vaccines companies,” says Emma Walmsley, Chief Executive Officer, GSK. “By combining our scientific expertise, technologies, and capabilities, we believe that we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19.”
The combination of a protein-based antigen together with an adjuvant is well-established and used in several vaccines available today. An adjuvant is added to some vaccines to enhance e immune response and has been shown to create a stronger and longer-lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.
The companies plan to initiate phase I clinical trials in the second half of 2020 and, if successful, subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.
FURTHER FACTS AGANIST CITRON AND FILED CLASS-ACTION EFFORTS
Where are the Twitter Tweets of the law firms filing or that Citron subjective feelings on the GlaxoSmithKline and Sanofi? They are certainly missing their Tweets on $GSK and $SNY as maybe a short-selling candidate’s as Citron had chosen Inovio $INO in their development of a vaccine in a 3 hour start-up period. Remember, INO-4700 was already in active Phase 1 / 2 trials during Summer 2019. The tweaking and following FDA guidelines as well as W.H.O.guidlines with INO-4800 before applying for FDA approvals as clearly stated by Dr. Kim, CEO of Inovio Pharmaceuticals. Make no mistake, we still don't agree with the further delusion of shareholder value by the newest agreement by Inovio and Stifel Nicholas 150 million share offer but know they can use these proceeds for bringing their robust drug pipeline to final market with FDA approvals.
WHAT'S THE FINAL TRADING MESSAGE
Time to send the message for the Institutional Investors to run back into ownership--long positions, and bring the bullish goring of the short-selling bears on $INO to break their trading funds within their banks...
Read my other articles on TalkMarkets here.
Disclosure: Currently holding a Long position within Inovio, INO.
How has your opinion on this changed since it was first written?
What will bring all back to work! Joe Biden is clueless... Keeping the eyes on the prize! POTUS Capricor, CAPR yesterday, beat on all numbers and has brought a VLP Vaccine into the long-term solutions FDA TRIALS CAP-1002. talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon PT $14 - $24 3-12 month outlook.
Keeping the eyes on the prize:
Good connecting article for why the PT had hit the 52 weeks high $12.32 and maybe the reason for the August 6th or 8th earnings report in jacking the share price towards becoming a true M&A candidate or given the blessings of the FDA's approval for CAP-1002 BLA filing for uses.
READ:
talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon
READ:
endpts.com/microcap-capricor-soars-on-interim-phii-dmd-data-showing-functional-benefit-for-older-patients/
Very Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching. READ: bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals. Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status. READ: talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets. This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L. Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies. Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347 READ: https://clinicaltrials.gov/ct2/shoVery Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching. READ: bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals. Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status. READ: talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets. This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L. Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies. Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347 READ: https://clinicaltrials.gov/ct2w/NCT04338347
Thanks.
Great article, looking to read more by you.
I was emailed by a few who have read the article. Hopefully it’s helping those trying to invest within INO against the backdrop, understand High-Frequency Traders, who are in this case, Short-Selling based on Citron Twitter Tweet. Our advantage is when they drive share price downward by hitting all the Buy Order Bids and then quickly must buy BACK ON THE ASK SIDE TO COVER THEIR SHORT BORROWING OF SHARES. Our trick of the trade, comes with recognizing the Block Trade indications. For myself, I keep the TotalView of all the Market Makers and the depth in liquidity on ip side and down side ranges. When this is accomplished, I automate my trade triggers to run the Buy and Sell triggers for open orders taking advantage when HFTs are quite identifiable in the increasingly higher volumes seen in your favorite charting systems. I use Point & Figure Charting as its really fined tuned in playing safely with the likes of High-Frequency folks working their Day-Trading need to cover their positions in buying back the INO shares used against those holding Long positions with INOVIO projected 1st Price Target, and then 2nd PT with dollar cost adjusted Averaging within your Long Position Entry. Remember, this one of my greatest rules of NO EMOTIONS just money math with Selling at least 50% to 75% of position when you can see the upward movement in gains equals the original dollar cost averaging of all Purchase Orders ententes, at this point you now are just in the market with the Houses or better said, Market Makers Bank Account or Cash They have within working their daily playbook on INO Share Price Trading Metric of working the markets. So, again, keeping your eyes on the prize is your secret of smartly investing in a quite volatile marketplace with the forces of economic damages wreaked by China’s Novel Coronavirus COVID19 L. Hopefully this makes sense, due in part, as they help Push share price with downward pressure, but they have a harder problem and cannot control the underlying upward pressure of many Institutional Investors, as well as Retail Investors, seeing the Great Reward v Risk in the upside for Inovio INO knowing all these High-Frequency Traders must cover their Short Trade of repaying where they borrowed these shares from Large Market Makers as what makes INO quite explosive for upward or upside momentum with, again, INO is quite ripe if PT of $26 -$36 a share in near term and much higher in achieving the second PT at $68 - $78 dollars a share. Great Swing-Trading Stock issue as Inovio offers as well as purchasing Options that are well seeing greater Open Interest on Call contracts, over the Open Interest on Put Options. Always watch your entry and protect and persevere your capital when investing in any stock securities.
What kind of questions did people email you about this? I'd love to read a follow up.
Notes for Friday 24, 2020 8:00p.m. Wow! Over 129 + million shares changing hands today. Never could imagine the forces of High-frequency Trader(s), and the loss of control to the upside biases of what they can’t control. The jury has come in and sent all the Threatened or Actual Class Action Suits against Inovio Pharmaceuticals, Inc., as Tweeted and broadcasted, finds on behalf of INO. PT Reminder that we still believe the $37 - $48 as Moderma, Inc., MRNA share price at PT. around $40s - $60 + near-term range. Always trade safely, with keeping your EMOTIONS AT THE TRADING DOOR, and the majority of your trades should do quite well; as its the End-Game that ultimately counts. Be safe and keep praying, as a society, especially for those helping those battling for their lives, and for those who have suffered more than we can imagine; during this China Born Novel Coronavirus COVID19 Pandemic. We, Will, Survive; with keeping God always within the equations—Rebuilding Our Cities, Counties, States, our Country, and our World aa we are more closely connected then we could ever imagine.
First, Covid 19 was not born in China! lol
u should read more news then write these stupid articles
Really Zachary? Then where did the virus originate?
Seriously Zachary? So where do you think COVID-19 started? Outerspace? A parallel dimension? Lets stick with reality here.
Sorry, but according to the World Health Organization, and every single country in the world, except China, all agree it originated in China. I know China wants to pretend that was not the case, but it is. I don't blame China, it's not like they did it on purpose, that's just where the virus happened to originate. It could have happened anywhere.
Some in America want to blame China for the deaths here, but that's just trying to pass the buck. America has no one to blame but itself - we had plenty of warning to prepare and did nothing.
NY Post Article brings greater light upon Inovio’s Vaccine efforts nypost.com/.../coronavirus-vaccine-enters-human-testing-trial/.
Good read, thanks.
Thank you...
Thank you for your incredible High-Frequency Trading Volumes today. Great entry points on the lows, which I will take advantage once the 72 hour clears the SEC 72 Hour insider trading rules seemingly broken by the actions by Citron Research Analyst, and all the law-firms who try driving down Shareholders Values as I covered within this article yesterday.